Novo Nordisk A/S (NVO)
Last Price$88.15.2%
Market Cap$392.3B
LTM Free Cash Flow
DKK 9,694.1M
Reverse DCF (Implied FCF growth)
9.9%
3Y Free Cash Flow CAGR
13.7%
LTM Revenue
DKK 40.2B
Reverse DCF (Implied Revenue growth)
9.5%
at normalized FCF margin 24.9%
3Y Revenue CAGR
27.3%
NVO Reverse DCF Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
NVO Free Cash Flow
Crunching data... Almost there!
NVO Growth
Crunching data... Almost there!
NVO vs Peer Set: Reverse DCF comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for NVO
DCF value calculator
Peter Lynch Fair Value
Discount rate
Relative Value
Earnings growth model
Peter Lynch charts
Margin of safety
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
FAQ
What is Novo Nordisk A/S Reverse DCF (discounted cash flow) valuation?
As of Dec 31, 2024, Novo Nordisk A/S's Reverse Discounted Cash Flow (DCF) valuation estimates its Free Cash Flow growth at 9.9%.
What is Novo Nordisk A/S WACC?
As of Dec 31, 2024, Novo Nordisk A/S's Weighted Average Cost of Capital (WACC) is approximately 7.6%.
What is Novo Nordisk A/S Free Cash Flow?
As of Dec 31, 2024, Novo Nordisk A/S's Free Cash Flow is DKK 9,694.1M.